Can corporations be compassionate? Rice University researchers are figuring that out. Pexels

Since the early 2000s, the business of doing business has changed its looks markedly. As corporations gain power and reach, many in the public are subjecting them to increasingly insistent questions about their impact on the lives of workers, the environment and society at large.

At the same time, academics have focused more attention on compassion in management and business organizations. Today, considerable research parses the way corporate conduct affects employees, laid-off workers and the well-being of society as a whole. A considerable segment of this academic literature advocates for what once seemed like an oxymoron: compassion in corporate management.

Most of the recent research on compassion focuses on individuals and the group. Most management research, meanwhile, centers on economic performance and efficiency. In an editorial for Journal of Management, though, Rice Business Mary Gibbs Jones Professor Emeritus of Management Jennifer George argues that compassion research can actually be a jumping-off point for focus on social problems, well-being and identifying the conditions under which organizations do the least harm.

But what is compassion in business, exactly? According to George, it's the practice of setting up organizations so that they respond to the vulnerable groups in their orbit. To do this, George says, companies should reconsider the concept of "American Corporate Capitalism (ACC)," which operates when corporations, workers and consumers pursue self-interest. ACC follows the laws of supply and demand, and is founded on the bedrock principles of respect for private property, an emphasis on economic growth and using profits as the measuring stick for making business decision.

Make no mistake, George adds: "ACC is an ideology." A host of institutions provide the underpinnings that allow ACC to flourish, among them the legal system, governmental agencies, stock markets, media and advertising and trade organizations.

But, notes George, the rewards from American Corporate Capitalism are narrowing sharply. ACC, she contends, now concentrates benefits upon fewer and fewer people. One article she cites suggests that outsized CEO salaries and compensation, coupled with large income inequality within a company, may result in organizations that do harm to their workers.

In fact, "the tenets of ACC seem to downplay the importance of compassionate organizing," says George. Harm done by corporations, such as laying off employees, may occur unintentionally, but those decisions still cause suffering. ACC, she says, "has the potential to create conditions under which compassion is much less likely to occur."

As a result, it's crucial to closely examine the tensions and contradictions between ACC and compassion. A focus on compassion would "identify the conditions under which organizations inflict the least harm and alleviate the most suffering," George writes.

She proposes a wide-ranging agenda to achieve this. First, researchers should look at organizational decision-making to track the influence of ACC values and whether criteria such as dominance or hierarchy override harmony and egalitarianism. Identifying the factors that spur organizations to favor only shareholders and customers over employees and neighboring communities could offer insights for management. Other research, George suggests, ought to examine a range of companies operating in the same sector, tracing which cause more damage and which are more successful at reducing suffering.

Finally, George says, academics should develop case studies of organizations that successfully pursue policies such as employing the disabled – policies designed to promote the well-being of vulnerable groups inside and outside the company.

Because corporations wield such vast influence, the harm they do can reach wide swaths of the population. It's time, George writes, for researchers to examine the disconnects between prevailing corporate culture and compassion. Effectively done, she says, such research could vault over the ivory battlements into the heart of everyday life.

------

This story originally ran on Rice Business Wisdom in 2019.

Based on research from Jennifer M. George, the Mary Gibbs Jones Professor Emeritus of Management in Organizational Behavior at the Jones Graduate School of Business at Rice University.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

New accelerator for AI startups to launch at Houston's Ion this spring

The Collectiv Foundation and Rice University have established a sports, health and wellness startup accelerator at the Ion District’s Collectiv, a sports-focused venture capital platform.

The AI Native Dual-Use Sports, Health & Wellness Accelerator, scheduled to formally launch in March, will back early-stage startups developing AI for the sports, health and wellness markets. Accelerator participants will gain access to a host of opportunities with:

  • Mentors
  • Advisers
  • Pro sports teams and leagues
  • University athletics programs
  • Health care systems
  • Corporate partners
  • VC firms
  • Pilot projects
  • University-based entrepreneurship and business initiatives

Accelerator participants will focus on sports tech verticals inlcuding performance and health, fan experience and media platforms, data and analytics, and infrastructure.

“Houston is quickly becoming one of the most important innovation hubs at the intersection of sports, health, and AI,” Ashley DeWalt, co-founder and managing partner of The Collectiv and founder of The Collectiv Foundation, said in a news release.

“By launching this platform with Rice University in the Ion District,” he added, “we are building a category-defining acceleration engine that gives founders access to world-class research, global sports properties, hospital systems, and venture capital. This is about turning sports-validated technology into globally scalable companies at a moment when the world’s attention is converging on Houston ahead of the 2026 World Cup.”

The Collectiv accelerator will draw on expertise from organizations such as the Rice-Houston Methodist Center for Human Performance, Rice Brain Institute, Rice Gateway Project and the Texas Medical Center.

“The combination of Rice University’s research leadership, Houston’s unmatched health ecosystem, and The Collectiv’s operator-driven investment platform creates a powerful acceleration engine,” Blair Garrou, co-founder and managing partner of the Mercury Fund VC firm and a senior adviser for The Collectiv, added in the release.

Additional details on programming, partners and application timelines are expected to be announced in the coming weeks.